Navigation Links
BHI Elects MedImmune's Reg Seeto, M.D. to Board of Directors
Date:12/19/2013

ROCKVILLE, Md. and BALTIMORE, Dec. 19, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that Reg Seeto, M.D., has been appointed to the BHI Board of Directors. Dr. Seeto currently serves as Vice President, Head of Partnering & Strategy at MedImmune, the global biologics research and development arm of AstraZeneca. 

"It is a pleasure to welcome Reg to the BHI Board of Directors," said Doug Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. "Reg's background in business development and partnering strategy will be an important asset to our Board as we give counsel to BHI in its fostering of startups in Central Maryland. We look forward to his contributions to this Board, to the BHI organization, and to the biohealth startup community."

Dr. Seeto rejoined the MedImmune Leadership Team in 2013 to lead the Partnering and Strategy Group after having spent a year as an executive abroad for AstraZeneca. He is responsible for MedImmune's Business Development and Strategy teams, which deliver external partnership strategy for the organization.

"It is an honor to be appointed to the BHI Board of Directors," said Dr. Seeto. "MedImmune has a strong interest in strengthening Maryland as a premiere bioscience cluster, and I look forward to working with BHI to advance its mission of developing Central Maryland into a center for commercialization and entrepreneurialism."

From 2011 to 2012, Dr. Seeto was on an expatriate assignment as the President of AstraZeneca Thailand, where he was the first MedImmune executive to participate in a talent exchange and development program with AstraZeneca. Under his leadership, the organization achieved its sales targets for the first time in five years and was awarded a company leadership award for management of the country's worst floods in more than half a century.

Dr. Seeto originally joined MedImmune in 2008 as the Vice President of Global Strategic Marketing and Portfolio Management where he worked closely with the R&D leadership team.  He was later promoted to the MedImmune Executive Team (MET) and established the Corporate Development and Strategy Group. Dr. Seeto has previous experience with Schering Plough/Organon Biosciences and Boehringer Ingelheim Pharmaceuticals. His earlier work experience included serving as a consultant at McKinsey & Company and he started his career as a medical doctor involved in both clinical practice and research. He has also served as first author for papers published in peer-reviewed journals. Dr. Seeto holds his medical degree (with honors) from the University of Sydney, Australia

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.


'/>"/>
SOURCE BioHealth Innovation, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Angeion Selects Hendrik Struik for Board of Directors
2. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
3. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
4. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
5. Pokagon Band of Potawatomi selects iSALUS Healthcares OfficeEMR™ Solution
6. ICON Medical Imaging Selects AG Mednet to Give Clinical Trial Sponsors Zero-Delay Efficiency and Faster Decision-Making Results
7. Four-Time Triathlon World Champion Melanie McQuaid Selects Polar USA as Official Heart Rate Training Solution
8. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
9. The Jewish Hospital - Mercy Health Selects Remedy Informatics ComprehensiveBMT Product
10. GE Healthcare Selects PS320 Fetal Simulator for Corometrics monitor fleet
11. BD Board of Directors Elects Rebecca W. Rimel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):